JP2019501130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501130A5 JP2019501130A5 JP2018526565A JP2018526565A JP2019501130A5 JP 2019501130 A5 JP2019501130 A5 JP 2019501130A5 JP 2018526565 A JP2018526565 A JP 2018526565A JP 2018526565 A JP2018526565 A JP 2018526565A JP 2019501130 A5 JP2019501130 A5 JP 2019501130A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 102000003800 Selectins Human genes 0.000 claims 7
- 108090000184 Selectins Proteins 0.000 claims 7
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 1
- 208000012634 Venoocclusive liver disease Diseases 0.000 claims 1
- SVEKJHBWJWHXKV-UHFFFAOYSA-N benzylsulfamic acid Chemical compound OS(=O)(=O)NCC1=CC=CC=C1 SVEKJHBWJWHXKV-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000017455 cell-cell adhesion Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 0 *c1c2C(NCc3ccccc3)=CC=*=Cc2cc(S(O)(=O)=O)c1 Chemical compound *c1c2C(NCc3ccccc3)=CC=*=Cc2cc(S(O)(=O)=O)c1 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262155P | 2015-12-02 | 2015-12-02 | |
| US62/262,155 | 2015-12-02 | ||
| PCT/US2016/064189 WO2017095904A1 (en) | 2015-12-02 | 2016-11-30 | Heterobifunctional pan-selectin antagonists having a triazole linker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501130A JP2019501130A (ja) | 2019-01-17 |
| JP2019501130A5 true JP2019501130A5 (enExample) | 2020-01-09 |
Family
ID=57681725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526565A Pending JP2019501130A (ja) | 2015-12-02 | 2016-11-30 | トリアゾールリンカーを有するヘテロ二官能性の汎セレクチン拮抗剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200171005A9 (enExample) |
| EP (1) | EP3383882A1 (enExample) |
| JP (1) | JP2019501130A (enExample) |
| CA (1) | CA2950088A1 (enExample) |
| WO (1) | WO2017095904A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045542T2 (hu) | 2014-12-03 | 2019-12-30 | Glycomimetics Inc | E-szelektinek és CXCR4 kemokin receptorok heterobifunkcionális inhibitorai |
| US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
| US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
| EP3522931A1 (en) | 2016-10-07 | 2019-08-14 | GlycoMimetics, Inc. | Highly potent multimeric e-selectin antagonists |
| CA3054605A1 (en) | 2017-03-15 | 2018-09-20 | Glycomimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| EP3717013A1 (en) | 2017-11-30 | 2020-10-07 | GlycoMimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| CA3085356A1 (en) * | 2017-12-29 | 2019-07-04 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectin and galectin-3 |
| EP3761994A1 (en) | 2018-03-05 | 2021-01-13 | GlycoMimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| WO2020219419A1 (en) * | 2019-04-24 | 2020-10-29 | Glycomimetics, Inc. | Multimeric pan–selectin antagonists |
| BR112022003186A2 (pt) * | 2019-08-20 | 2022-05-17 | Glycomimetics Inc | Processo para preparar intermediário de inibidor de e-selectina |
| WO2021195465A1 (en) * | 2020-03-27 | 2021-09-30 | Magnani John L | Treatment of acute respiratory distress syndrome and related conditions with antagonists of e-selectin |
| WO2021247396A1 (en) | 2020-05-31 | 2021-12-09 | Magnani John L | Compounds and methods for reduction of cancer cell burden and protection of normal hematopoiesis |
| JP2023529485A (ja) | 2020-06-14 | 2023-07-10 | グリコミメティクス， インコーポレイテッド | Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法 |
| WO2023014690A1 (en) | 2021-08-03 | 2023-02-09 | Glycomimetics, Inc. | Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003301209A1 (en) * | 2002-12-20 | 2004-07-22 | Glycomimetics, Inc. | Oligosaccharides and conjugates thereof for the treatement of pseudomonas bacteria infection |
| CN103626813B (zh) | 2005-09-02 | 2017-05-03 | 糖模拟物有限公司 | 异型双功能全选择素抑制剂 |
| US8895510B2 (en) * | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| US8921328B2 (en) * | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
-
2016
- 2016-11-30 CA CA2950088A patent/CA2950088A1/en not_active Abandoned
- 2016-11-30 US US15/781,072 patent/US20200171005A9/en not_active Abandoned
- 2016-11-30 WO PCT/US2016/064189 patent/WO2017095904A1/en not_active Ceased
- 2016-11-30 JP JP2018526565A patent/JP2019501130A/ja active Pending
- 2016-11-30 EP EP16820045.9A patent/EP3383882A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501130A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2016534134A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2014511892A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2013518050A5 (enExample) | ||
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| JP2015517574A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2015509535A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2014508804A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) |